Mycoplasma hominis, the first mycoplasma of human origin to be isolated, has been associated with several diseases, notably bacterial vaginosis, pelvic inflammatory disease, prematurity and puerperal fever. The mouse model does not mimic closely these features of human disease, but has some notable features. Given intravaginally to mice, M. hominis does not colonize unless the mice have been pre-treated with oestradiol. As shown here, endogenous hormone has no part to play because removal of the ovaries does not interfere with vaginal colonization. Persistent colonization occurs in hysterectomized mice so that organisms in the upper tract, which are sometimes found, are not responsible, by retrograde leakage, for those in the lower tract. Organisms in the lower tract can be eliminated by treating mice with a tetracycline, or progesterone or by natural resolution. Elimination by whatever means results in a rather weak immunity to recolonization. In contrast, intravenous inoculation of viable, and particularly killed, M. hominis organisms results in strong resistance to recolonization. This is, in part, genetically influenced, being seen in mice of strain BALB/c but not of strain CBA. Resistance is inversely proportional to the presence and titre of M. hominis specific serum antibody. The possible role of cell-mediated immunity is discussed.
INTRODUCTION
The first report of the isolation of a mycoplasma from a human subject was in 1937 (Dienes & Edsall, 1937) . The organisms were recovered, apparently in pure culture, from an abscess of Bartholin's gland. In retrospect, these organisms, which produced large colonies on agar, probably belonged to the species Mycoplasma hominis because this is the large-colony-forming species most frequently recovered from the genital tract. Over the last 70 years, the fact that this mycoplasma has been found as part of the normal flora of the human genital tract has complicated significantly clarification of its role in disease (TaylorRobinson, 1996) . Nevertheless, it seems to have some role, to a greater or lesser extent, in upper urinary tract infections, bacterial vaginosis, pelvic inflammatory disease, prematurity, post-partum and post-abortal fever and respiratory distress in the newborn (Totten et al., 2008) . M. hominis has been implicated also in some extra-genital infections, such as central nervous system and surgical wound infections and suppurative arthritis seen in individuals with hypogammaglobulinaemia . In a proportion of these conditions, a specific antibody response has also been detected which might be protective in the genital tract. This has never been established but the results of a study in which adult volunteers were given M. hominis organisms via the respiratory tract showed that those who possessed indirect haemagglutinating antibody were protected from the development of sore throats and cervical (neck) adenopathy (Taylor- Robinson et al., 1965) . This apart, there is no information on the role of antibody in M. hominis infection. The fact that M. hominis has been shown to infect the genital tract of oestradiol-treated female mice (Furr & Taylor-Robinson, 1989 ) opens an opportunity of exploring the protective effect or otherwise of antibody in the mouse model and may allow inferences to be drawn regarding human infection and disease.
Inoculum and mouse inoculation. M. hominis strain MY17288 (our designation) was received originally from the late Dr B. E. Andrews (PHLS Laboratory, Norwich, UK) having been isolated from the blood of a woman with puerperal fever. It was subcultured three times in liquid medium before intravaginal or intravenous inoculation of the mice. Mice inoculated intravaginally were given 50 ml instilled with an Eppendorf pipette. This inoculation coincided with the second dose of oestradiol.
Vaginal cytology. A vaginal nasopharyngeal swab (Medical Wire and Equipment) was inserted into the mouse vagina, rotated, removed and then rolled along a 3"61" glass slide. The smear was fixed for 30 min in methanol and then stained with Giemsa. The phase of the reproductive cycle was determined by assessing the presence or absence of leukocytes and nucleated and cornified squamous epithelial cells (Rugh, 1968; Furr & Taylor-Robinson, 1991) . Following a dose of oestradiol and before receiving M. hominis, the mice were proved to be in the oestrous phase of the cycle by vaginal cytology.
Isolation and quantification of M. hominis. The remaining contents of the vaginal swab were expressed in 1.8 ml liquid medium contained in a screw-capped glass vial of 2.5 ml capacity. This was regarded as a 10 21 dilution and further 10-fold dilutions were made serially to 10
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, after which the vials were incubated at 37 uC and observed every day for up to 2 weeks. Presumptive growth of M. hominis was indicated by a change in colour of the medium from yellow to pink. The last dilution at which a colour change occurred was deemed to contain 1 colour-changing unit (c.c.u.) of M. hominis (Taylor- .
Antibiotic treatment. Some mice were treated with oxytetracycline (Occrycetin; Willows Francis Veterinary), 6.0 mg in 0.1 ml, given subcutaneously daily for 4 days (Taylor- Robinson & Furr, 2000) .
Measurement of antibody. Antibody to M. hominis was sometimes sought in sera and vaginal washings. A washing was obtained by introducing 50 ml Dulbecco's PBS into the vagina using an Eppendorf pipette, reintroducing the fluid and withdrawing it. Washings and sera were inactivated at 56 uC for 30 min before being tested by use of the metabolism-inhibition technique using strain MY17288 of M. hominis.
Statistical evaluation. Groups of mice were compared using Fisher's exact test where appropriate. A probability (P) value of ,0.05 was regarded as significant.
RESULTS
Vaginal colonization of BALB/c and CBA mice by M. hominis Previous observations (Furr & Taylor-Robinson, 1993) had indicated that BALB/c mice were more susceptible to Mycoplasma pulmonis (of murine origin) than were CBA mice. Thus, the susceptibility of these two mouse strains to vaginal colonization by M. hominis after pre-treatment with oestradiol was compared. Of 20 BALB/c mice inoculated with 5610 6 c.c.u. of M. hominis, 19 (95 %) were colonized vaginally after 1 week, 16 after 3 weeks (titre range: 10 4 -10 8 c.c.u.) and 10 after 8 weeks (titre range: 10 3 -10 7 c.c.u.) with the organisms persisting in two mice for up to 100 days. Of 20 CBA mice given the same size inoculum, 18 (90 %) were colonized and the organisms persisted at a titre and for a duration similar to that seen in the BALB/c mice. Apart from a transient initial recovery of organisms in small numbers, sustained colonization of these strains of mice did not occur if they were pre-treated with progesterone instead of oestradiol.
Effect of ovariectomy on genital tract colonization by M. hominis
To determine the effect of naturally occurring oestrogen on colonization, the ovaries of 20 BALB/c mice were excised, a further group of mice without surgery being used as a control. Ten mice from each group received the usual regime of oestradiol, the other 10 remaining untreated. All 40 mice were each inoculated intravaginally with 2.5610 7 of M. hominis. As shown in Table 1 , the vaginal colonization of mice that were not ovariectomized was no more frequent or greater than in ovariectomized mice that were given oestradiol. In other words, it seems that naturally occurring hormone did not make a significant contribution to colonization.
Effect of hysterectomy on genital tract colonization by M. hominis
It had been observed at autopsy previously (Furr & TaylorRobinson, 1989 ) that M. hominis existed not only in the vagina, but sometimes in the uterine horns and ovaries and very occasionally in the throat of mice several weeks after intravaginal inoculation. This raised the question of whether the primary site of colonization might be in the upper genital tract, recovery of organisms from vaginal swabs simply being a reflection of their transmission from above. In an attempt to resolve this question, BALB/c mice in two groups of five were hysterectomized at 3 weeks of age, allowed to recover and at 7 weeks one group began the usual regime of oestradiol. Two other groups of five mice that had not been hysterectomized were treated similarly, one group being given oestradiol and the other remaining untreated. At the time of the second dose of oestradiol, all 20 mice were challenged intravaginally with 2.5610 7 c.c.u. of M. hominis. After 7 and 14 days, large numbers of organisms were recovered from the vagina of hysterectomized mice given oestradiol and from those given oestradiol only, but not from hysterectomized or normal control mice that had not received oestradiol. The results suggest that hysterectomy did not prevent vaginal colonization and that infection at a site in the upper tract was not paramount for this to occur.
Eradication of M. hominis from the vagina
Previous experience had indicated that eradication could be achieved by treating the mice with oxytetracycline, or by administering progesterone, or by leaving the mice until the organisms had disappeared spontaneously. In the current experiment (Table 2) , of ten BALB/c mice and ten CBA mice that had been colonized vaginally and then treated with the antibiotic, nine of the BALB/c mice and seven of the CBA mice were mycoplasma-free 14 days later and thereafter. Likewise, of nine mice of each strain given progesterone, all were mycoplasma-free after 14 days and subsequently. In addition, of five BALB/c mice and ten CBA mice colonized initially, four of the former and eight of the latter were shown by 56 days to have become mycoplasma-free without any intervention. Thus, this was slow compared to the rapid clearing of organisms following antibiotic or progesterone administration, of which progesterone treatment seemed marginally to be the most effective.
Vaginal colonization of mice previously infected vaginally
As shown in Table 2 , groups of BALB/c and CBA mice infected with M. hominis were treated as described above and then those from which M. hominis could not be recovered were rechallenged vaginally at the time of a second dose of oestradiol in a further course of the hormone. Of 22 BALB/c mice that were M. hominis-free, 15 (68 %) were susceptible on rechallenge; of 24 mycoplasmafree CBA mice, 21(87 %) were susceptible, a difference that was not significant (P50.2, Fisher's exact test). All mice that had not received M. hominis previously were susceptible to vaginal colonization. Overall, therefore, resistance to vaginal colonization was poor in mice that had recovered from a previous successful challenge.
Vaginal colonization after intravenous inoculation of M. hominis
Viable M. hominis organisms. Three groups, each of 10 BALB/c mice, were used. The first group received two intravenous inocula, 14 days apart, each of 5610 6 c.c.u. of viable M. hominis. After a further 21 days, the inoculated mice, together with a group of 10 uninoculated controls, received the first of four doses of oestradiol. The second dose, 1 week later, coincided with the intravaginal inoculation of 2.5610 7 c.c.u. of M. hominis, after which the mice were swabbed at intervals to determine whether vaginal colonization had occurred and persisted. As shown in Table 3 , only two of the mice became colonized, one of these transiently, in contrast to the control mice, six of which were still colonized after 42 days. Thus, intravenous inoculation of viable organisms afforded at least 80 % protection against vaginal colonization.
After a further 2 weeks (day 56), the original inoculated BALB/c mice, together with a new group of controls of similar age, were started on a course of oestradiol and inoculated intravaginally with 2.5610 7 c.c.u. of M. hominis. On this occasion, two of the mice inoculated previously were again positive transiently in comparison with the controls, nine of which became positive vaginally. Thus, it was clear that protection against vaginal colonization by M. hominis could be afforded by intravenous immunization with viable organisms. In complete contrast, however, this was not seen with CBA mice. Thus, of 10 such mice given 5610 6 c.c.u. of viable M. hominis intravenously, all were colonized vaginally 7 and 14 days after receiving 2.5610 7 c.c.u. of M. hominis intravaginally, in exactly the same way as 10 controls that had not been inoculated intravenously. Thus, there was no evidence of vaginal protection.
To make certain that the difference noted between the BALB/c and CBA mice was not spurious, two groups of ten mice comprising the two strains were inoculated intravenously with 5610 7 c.c.u. of viable M. hominis. After a further 2 weeks, both groups were inoculated again with Table 4 , apart from the transient existence of a small number of M. hominis organisms in one BALB/c mouse, all ten of these mice were fully protected whereas, in contrast, only three of nine CBA mice were protected, a difference that was statistically significant (P50.01, Fisher's exact test).
Killed M. hominis organisms. The protective effect of M. hominis, killed by heating at 56 u C, given to BALB/c mice intravenously was assessed. Viable M. hominis was used for comparison. Of three groups, each of 10 mice, the first received 5610 7 c.c.u. of killed organisms, followed by 5610 8 c.c.u. 14 days later. The second group was given similar inocula of viable organisms. The third group received arginine-containing medium and served as an unvaccinated control. One month after the second inoculation, oestradiol was given and again 1 week later, at which time mice in the three groups were challenged intravaginally with 2.5610 7 c.c.u. of M. hominis. The results presented in Table 5 show that killed M. hominis organisms were at least as effective, if not more so, than viable ones in protecting BALB/c mice against intravaginal challenge with M. hominis.
In contrast, an identical experiment undertaken in CBA mice with viable or killed organisms (Table 5) showed that they did not induce any protection against intravaginal challenge, a difference that was statistically significant (P ,0.005, Fisher's exact test).
Relation of serum antibody to protection against vaginal colonization
In previous experiments in the current study in which BALB/c mice were used, there were 18 animals that had been colonized with M. hominis after intravaginal inoculation, but were then free of mycoplasmas and had metabolism-inhibiting serum antibody titres of 1 : ,16. Of these, 15 (83 %) became recolonized after intravaginal challenge. There were 6 mice that had also been colonized with M. hominis after intravaginal inoculation; they became free of the organisms but had antibody titres of 1 : 32 or greater. Of these, only one (16 %) became recolonized after intravaginal challenge.
In the experiments in which mice were given viable M. hominis organisms intravenously, a range of metabolisminhibiting antibody titres from 1 : ,16 to 1 : 512 (geometric mean of 1 : 120) was seen. The mouse having an antibody titre of 1 : ,16 was susceptible to vaginal colonization, whereas all those with higher antibody titres were resistant. Mice receiving killed organisms exhibited antibody titres ranging from 1 : 32 to 1 : 128 (geometric mean of 1 : 56). None of these mice was susceptible to vaginal colonization. All control mice unexposed previously to M. hominis had antibody titres of 1 : ,8 and all were colonized when challenged intravaginally. Antibody was not detected in any of the vaginal washings.
DISCUSSION
It was shown previously (Furr & Taylor-Robinson, 1989 ) that the prototype strain (PG 21) of M. hominis was incapable of colonizing the genital tract of mice probably because of the large number of passes it had received in vitro. Thus, in this study, the MY17288 strain of M. hominis was used and several unresolved issues have been addressed. Oestrogen occurring naturally in the mouse makes no contribution to the ostensible vaginal colonization by M. hominis. Endogenous oestrogen might play a part if the dose of oestradiol administered was much smaller. Apart from the influence of the oestradiol dose on the duration of recovery of organisms from the vagina, the size of the M. hominis inoculum in terms of the number of c.c.u. was important. As shown previously (Furr & Taylor-Robinson, 1989 ), recovery could be made to extend beyond 200 days in a few mice. However, a relatively large dose was used to ensure a continued effect. It is also clear from the observations on hysterectomized mice that the continued existence of organisms in the lower genital tract is unlikely to be due to 'reseeding' from those that have colonized the upper tract. As might be expected, transmission is from the lower to upper tract. For convenience we refer to colonization of the lower genital tract as vaginal colonization when, in fact, vaginal swabbing does not allow a distinction to be made between colonization of the vagina and colonization of the uterine cervix. The truth, based on scanning and immunoelectron microscopical observations (Furr et al., 1995) , is that the cervix is the primary focus of colonization. This may also be the case in the human situation where M. hominis organisms 'picked up' on a vaginal swab could, in fact, originate from infection in the cervix.
Regarding the immunological aspects, attempts were made to understand the manner in which protection against vaginal colonization was induced. In the case of M. pulmonis, studied previously (Furr & Taylor-Robinson, 1984) , protection occurred following colonization of the genital tract. However, neither viable nor killed M. pulmonis organisms given intravenously prevented colonization on intravaginal challenge, despite the stimulation of high titres of specific serum antibody, although elimination of organisms from the genital tract of mice given viable organisms intravenously was faster than observed in mice given killed organisms (Taylor- . In the case of M. hominis, previous vaginal colonization and subsequent elimination of organisms resulted in the mice being protected poorly against rechallenge, although there was an inverse relation between the presence of serum antibody and protection; mice with antibody were protected, while those without were not. In addition, a result somewhat different from that seen with M. pulmonis was observed when viable or killed M. hominis organisms were given intravenously. Both viable and killed organisms provided protection and, again, there was an inverse relation with antibody stimulated in high titre. However, protection was seen only in BALB/c mice and not at all when CBA mice were used. This points to involvement of a genetic factor in the outcome of challenge in vaccinated mice, despite the response of both mouse strains to primary intravaginal challenge being similar, and indicates that the mechanisms of protection against M. pulmonis and M. hominis are not the same. 
